- Trials with a EudraCT protocol (577)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (6)
577 result(s) found for: Prothrombin.
Displaying page 1 of 29.
EudraCT Number: 2010-019250-41 | Sponsor Protocol Number: 220901 | Start Date*: 2010-05-27 | |||||||||||
Sponsor Name:Baxter Innovations GmbH | |||||||||||||
Full Title: AN INTERNATIONAL, MULTI-CENTRE, PROSPECTIVE, OPEN-LABEL, NON-RANDOMISED, UNCONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF PROTHROMPLEX TOTAL IN ORAL ANTICOAGULANT REVERSAL IN PATIENTS WITH A... | |||||||||||||
Medical condition: Acquired Deficiency of Prothrombin Complex Coagulation Factors (II, VII, IX, X) due to oral anticoagulant therapy with Vitamin K antagonists | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002204-24 | Sponsor Protocol Number: 1160.203 | Start Date*: 2014-12-17 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: REVERSAL OF ANTICOAGULANT EFFECT OF DABIGATRAN® BY PROTHROMBIN COMPLEX CONCENTRATE (BERIPLEX®) ASSESSED WITH A NOVEL METHOD OF BLOOD LOSS MEASUREMENT | ||
Medical condition: Healthy male volunteers. Study assessing the effect of a single 50IU/Kg dose of Beriplex on the anticoagulant effect of Dabigatran. This is of interest when rapid reversal of its effect is mandate... | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-002649-41 | Sponsor Protocol Number: LEX-209 | Start Date*: 2017-06-19 | |||||||||||
Sponsor Name:Octapharma Pharmazeutika Produktionsges.m.b.H | |||||||||||||
Full Title: A Phase III, randomized, double-blind, multicenter study to assess the efficacy and safety of OCTAPLEX, a four-factor prothrombin complex concentrate (4F-PCC), compared to the 4F-PCC Beriplex® P/N ... | |||||||||||||
Medical condition: Reversal of vitamin K antagonist (VKA) induced anticoagulation in patients needing urgent surgery associated with significant bleeding risk. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) PL (Completed) ES (Prematurely Ended) BG (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000309-34 | Sponsor Protocol Number: 7654321 | Start Date*: 2016-06-10 |
Sponsor Name:Medical University of Vienna | ||
Full Title: Vorapaxar in the human endotoxemia model | ||
Medical condition: LPS induced acute inflammatory state in healthy volunteers | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-001217-15 | Sponsor Protocol Number: 85/04/04 | Start Date*: 2004-09-16 |
Sponsor Name:Lassila Riitta | ||
Full Title: PRO-FEIBA. Asetelma on selkeä etenevä satunnaistettu kaksisuuntainen tutkimus aktivoitujen hyytymistekijöiden (aPCC, activated prothrombin complex concentrate) vaikutuksesta vaikeaa A hemofiliaa sa... | ||
Medical condition: A-hemofilia | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male | |
Trial protocol: FI (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-000392-33 | Sponsor Protocol Number: 2014PROPER3 | Start Date*: 2015-06-30 | |||||||||||
Sponsor Name:University Medical Center Groningen | |||||||||||||
Full Title: Fixed versus variable dosing strategy of prothrombin complex concentrate for bleeding complications of vitamin K antagonists | |||||||||||||
Medical condition: Major bleeding complications of vitamin K antagonists | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-004484-31 | Sponsor Protocol Number: Riva-PCC | Start Date*: 2014-01-10 | |||||||||||
Sponsor Name:Medizinische Universität Innsbruck / Allg. u. chirug. Intensivmedizin | |||||||||||||
Full Title: Rivaroxaban and PCC: Prothrombin Complex Concentrate in patients with bleeding complications related to Rivaroxaban | |||||||||||||
Medical condition: blood coagulation disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002828-85 | Sponsor Protocol Number: RG_15-114 | Start Date*: 2017-04-28 | |||||||||||||||||||||
Sponsor Name:University of Birmingham | |||||||||||||||||||||||
Full Title: Paediatric Hepatic International Tumour Trial | |||||||||||||||||||||||
Medical condition: Hepatoblastoma and Hepatocellular Carcinoma. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) IE (Ongoing) ES (Ongoing) NO (Completed) DE (Ongoing) CZ (Ongoing) BE (Ongoing) FR (Ongoing) NL (Ongoing) PL (Ongoing) AT (Ongoing) SE (Ongoing) FI (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-006870-22 | Sponsor Protocol Number: 1144/2022 | Start Date*: 2022-11-04 | |||||||||||
Sponsor Name:Medical University of Vienna | |||||||||||||
Full Title: Substitution of coagulation factors and blood products in patients with liver cirrhosis | |||||||||||||
Medical condition: Liver cirrhosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-004009-37 | Sponsor Protocol Number: MD2021.01 | Start Date*: 2021-11-05 | ||||||||||||||||
Sponsor Name:Prothya Biosolutions BV | ||||||||||||||||||
Full Title: A Phase 1/2 study of the dose-response in pharmacodynamics and safety of prothrombin complex concentrate Cofact in healthy subjects under vitamin K antagonist anticoagulation | ||||||||||||||||||
Medical condition: Treatment of bleeding and perioperative prophylaxis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Completed) CZ (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000740-21 | Sponsor Protocol Number: LEX-210 | Start Date*: 2022-04-08 | |||||||||||
Sponsor Name:Octapharma AG | |||||||||||||
Full Title: Study of four-factor prothrombin complex concentrate, OCTAPLEX, in patients with acute major bleeding on direct oral anticoagulant (DOAC) therapy with factor Xa inhibitor. | |||||||||||||
Medical condition: Acute major bleeding in patients receiving DOAC therapy with factor Xa inhibitor | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) IT (Ongoing) ES (Ongoing) AT (Ongoing) HR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004528-36 | Sponsor Protocol Number: CAC-002-01 | Start Date*: 2011-10-06 | |||||||||||
Sponsor Name:Asklepion Pharmaceuticals, LLC | |||||||||||||
Full Title: An open-label, single center, non-randomized, continuation study of cholic acid capsules in subjects with inborn errors of bile acid synthesis. | |||||||||||||
Medical condition: Patients with inborn errors of bile acid synthesis and metabolism | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003963-39 | Sponsor Protocol Number: CV185-066 | Start Date*: 2014-10-02 | |||||||||||
Sponsor Name:Bristol-Myers Squibb Company | |||||||||||||
Full Title: An In Vitro Comparison of Apixaban Activity in Adult and Pediatric Plasma | |||||||||||||
Medical condition: Thrombosis | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001748-39 | Sponsor Protocol Number: PHRC2013-01 | Start Date*: 2014-08-21 |
Sponsor Name:CHU d'Angers | ||
Full Title: TRAnexamic Acid for Preventing postpartum hemorrhage following a vaginal delivery : a multicenter randomised, double blind placebo controlled trial | ||
Medical condition: postpartum hemorrhage | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-002084-20 | Sponsor Protocol Number: Version_1.0_MP_and_anticoagulants | Start Date*: 2011-07-28 |
Sponsor Name:Medizinische Universität Wien; Universitätsklinik für Klinische Pharmakologie | ||
Full Title: A prospective, randomized, controlled open-label trial to investigate the effects of 10mg rivaroxaban or 110mg dabigatran on microparticle formation in critically ill patients compared to age-& sex... | ||
Medical condition: The effect of the used IMPs should be investigated in critically ill patients and healthy subjects | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2004-001319-71 | Sponsor Protocol Number: F1K-MC-EVBQ | Start Date*: 2004-08-13 |
Sponsor Name:Lilly S.A. | ||
Full Title: A Phase IIIb Study to Determine Efficacy and Safety of Extended Drotrecogin Alfa (Activated) Therapy in Patients With Persistent Requirement for Vasopressor Support After 96-Hour Infusion With Comm... | ||
Medical condition: in severe sepsis patients with persistent vasopressordependent hypotension | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-000285-38 | Sponsor Protocol Number: APHP190020 | Start Date*: 2019-08-21 |
Sponsor Name:London School of Hygiene and Tropical Medicine | ||
Full Title: Pharmacokinetics of Tranexamic Acid after oral, intramuscular or intravenous administration: a prospective, randomised, cross-over trial in healthy volunteers. | ||
Medical condition: healthy volunteers | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-005796-34 | Sponsor Protocol Number: CC-GEMSO-2007 | Start Date*: 2008-03-19 | |||||||||||
Sponsor Name:Universität Mainz, I. Medizinische Klinik und Poliklinik | |||||||||||||
Full Title: A randomized, double-blind, multicenter phase II trial with gemcitabine plus sorafenib versus gemcitabine plus placebo in patients with chemo-naive advanced or metastatic adenocarcinoma of the bili... | |||||||||||||
Medical condition: Patients with Adenocarcinoma of the gallbladder or intrahepatic bile ducts or histologically proven hepatic metastases of an earlier resected and histologically proven biliary tract cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002190-10 | Sponsor Protocol Number: UCDCRC/20/03 | Start Date*: 2021-02-05 |
Sponsor Name:University College Dublin | ||
Full Title: Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG) | ||
Medical condition: Coagulopathy of COVID-19 appears to afflict approximately 20% of patients with severe COVID-19 and is associated with need for critical care and death. COVID-19 coagulopathy is characterized by ele... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IE (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-004138-12 | Sponsor Protocol Number: TAK-330-3001 | Start Date*: 2022-10-25 | |||||||||||
Sponsor Name:Takeda Development Center Americas, Inc. | |||||||||||||
Full Title: A Phase 3, Prospective, Randomized, Open-label, Adaptive Group Sequential, Multicenter Trial with Blinded Endpoint Assessment to Evaluate the Efficacy and Safety of TAK-330 for the Reversal of Dire... | |||||||||||||
Medical condition: Patients on treatment with Factor Xa Inhibitor needing for an urgent intervention associated with a high risk of bleeding. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.